Our findings align with existing knowledge11,20,21 that the initial line of chemotherapy can modify the inhibitory landscape of the tumor and tumor microenvironment by enhancing PD-L1 levels, and such alterations can potentially enhance the PD-L1-mediated responsiveness of tumors to anti-PD-1 therapy. Here, CD274 is linked to neoplasm.